179 related articles for article (PubMed ID: 19933802)
1. Mode of action of Van-M-02, a novel glycopeptide inhibitor of peptidoglycan synthesis, in vancomycin-resistant bacteria.
Miura K; Yamashiro H; Uotani K; Kojima S; Yutsudo T; Lu J; Yoshida O; Yamano Y; Maki H; Arimoto H
Antimicrob Agents Chemother; 2010 Feb; 54(2):960-2. PubMed ID: 19933802
[TBL] [Abstract][Full Text] [Related]
2. Redesign of glycopeptide antibiotics: back to the future.
James RC; Pierce JG; Okano A; Xie J; Boger DL
ACS Chem Biol; 2012 May; 7(5):797-804. PubMed ID: 22330049
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin resistance: occurrence, mechanisms and strategies to combat it.
Boneca IG; Chiosis G
Expert Opin Ther Targets; 2003 Jun; 7(3):311-28. PubMed ID: 12783569
[TBL] [Abstract][Full Text] [Related]
4. Eremomycin pyrrolidide: a novel semisynthetic glycopeptide with improved chemotherapeutic properties.
Olsufyeva EN; Shchekotikhin AE; Bychkova EN; Pereverzeva ER; Treshalin ID; Mirchink EP; Isakova EB; Chernobrovkin MG; Kozlov RS; Dekhnich AV; Preobrazhenskaya MN
Drug Des Devel Ther; 2018; 12():2875-2885. PubMed ID: 30237697
[TBL] [Abstract][Full Text] [Related]
5. Structure diversification of vancomycin through peptide-catalyzed, site-selective lipidation: a catalysis-based approach to combat glycopeptide-resistant pathogens.
Yoganathan S; Miller SJ
J Med Chem; 2015 Mar; 58(5):2367-77. PubMed ID: 25671771
[TBL] [Abstract][Full Text] [Related]
6. Opposite effect of vancomycin and D-Cycloserine combination in both vancomycin resistant Staphylococcus aureus and enterococci.
Boudrioua A; Li Y; Hartke A; Giraud C
FEMS Microbiol Lett; 2020 Apr; 367(8):. PubMed ID: 32277698
[TBL] [Abstract][Full Text] [Related]
7. Synergism between beta-lactams and glycopeptides against VanA-type methicillin-resistant Staphylococcus aureus and heterologous expression of the vanA operon.
Périchon B; Courvalin P
Antimicrob Agents Chemother; 2006 Nov; 50(11):3622-30. PubMed ID: 16954318
[TBL] [Abstract][Full Text] [Related]
8. Maxamycins: Durable Antibiotics Derived by Rational Redesign of Vancomycin.
Wu ZC; Boger DL
Acc Chem Res; 2020 Nov; 53(11):2587-2599. PubMed ID: 33138354
[TBL] [Abstract][Full Text] [Related]
9. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling of Gram-positive bacteria peptidoglycan layer, selected glycopeptide antibiotics and vancomycin derivatives modified with sugar moieties.
Ślusarz R; Szulc M; Madaj J
Carbohydr Res; 2014 May; 389():154-64. PubMed ID: 24685455
[TBL] [Abstract][Full Text] [Related]
11. Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
Belley A; Harris R; Beveridge T; Parr T; Moeck G
Antimicrob Agents Chemother; 2009 Feb; 53(2):800-4. PubMed ID: 19029329
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl-D-leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria.
Printsevskaya SS; Pavlov AY; Olsufyeva EN; Mirchink EP; Isakova EB; Reznikova MI; Goldman RC; Branstrom AA; Baizman ER; Longley CB; Sztaricskai F; Batta G; Preobrazhenskaya MN
J Med Chem; 2002 Mar; 45(6):1340-7. PubMed ID: 11882003
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antibacterial activity of N4-mono alkyl derivatives of novel glycopeptide LYV07ww01.
Shao C; Zhou W; Zhang S; Wei W; Ruan L; Jin Y; Sun X; Huang Y
Bioorg Med Chem Lett; 2011 Nov; 21(22):6732-8. PubMed ID: 21978682
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
Leuthner KD; Vidaillac C; Cheung CM; Rybak MJ
Antimicrob Agents Chemother; 2010 Sep; 54(9):3799-803. PubMed ID: 20585126
[TBL] [Abstract][Full Text] [Related]
15. Glycopeptide antibiotic analogs for selective inactivation and two-photon imaging of vancomycin-resistant strains.
Ariyasu S; Too PC; Mu J; Goh CC; Ding Y; Tnay YL; Yeow EK; Yang L; Ng LG; Chiba S; Xing B
Chem Commun (Camb); 2016 Mar; 52(25):4667-70. PubMed ID: 26953360
[TBL] [Abstract][Full Text] [Related]
16. Heterologous expression of the enterococcal vanA operon in methicillin-resistant Staphylococcus aureus.
Périchon B; Courvalin P
Antimicrob Agents Chemother; 2004 Nov; 48(11):4281-5. PubMed ID: 15504853
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial activity of stilbene oligomers against vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) and their synergism with antibiotics.
Sakagami Y; Sawabe A; Komemushi S; All Z; Tanaka T; Iliya I; Iinuma M
Biocontrol Sci; 2007 Mar; 12(1):7-14. PubMed ID: 17408003
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin resistance in gram-positive cocci.
Courvalin P
Clin Infect Dis; 2006 Jan; 42 Suppl 1():S25-34. PubMed ID: 16323116
[TBL] [Abstract][Full Text] [Related]
19. Novel semi-synthetic glycopeptide antibiotics active against methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE): doubly-modified water-soluble derivatives of chloroorienticin B.
Yoshida O; Yasukata T; Sumino Y; Munekage T; Narukawa Y; Nishitani Y
Bioorg Med Chem Lett; 2002 Nov; 12(21):3027-31. PubMed ID: 12372494
[TBL] [Abstract][Full Text] [Related]
20. Oritavancin: mechanism of action.
Zhanel GG; Schweizer F; Karlowsky JA
Clin Infect Dis; 2012 Apr; 54 Suppl 3():S214-9. PubMed ID: 22431851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
